🟢 MMED is trading 4.5% up today on positive Phase 3 results for LSD-based depression therapy DT120

MMED is trading 4.5% up today at $14.36 after investors reacted to highly positive Phase 3 results for its LSD-based depression therapy, DT120.

• The company reported profound efficacy for DT120 in a major depressive disorder trial, a pivotal late-stage milestone that strengthens its psychedelic medicines pipeline.
• The successful trial results significantly bolster the company's commercialization prospects for its lead therapeutic candidate.
• While broader indices are trading modestly higher, the sharp move in MMED is primarily attributed to this company-specific clinical breakthrough.